Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Piper Jaffray Cuts Price Target on Orexigen Therapeutics (OREX) to $5 Following 4Q Results
February 29, 2016 8:13 AM ESTPiper Jaffray maintained an Overweight rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $5.00 (from $11.00), following the company's 4Q earnings report. US Contrave royalties of $2.6M, helped OREX end 2015 with $214M of cash, sufficient through profitability based on growing revenues. Orexigen reported 4Q15 revenues of $4.9M, including $2.6M in Contrave... More
UPDATE: RBC Capital Downgrades Orexigen Therapeutics (OREX) to Sector Perform
February 29, 2016 6:52 AM EST(Updated - February 29, 2016 8:24 AM EST)
RBC Capital downgraded Orexigen Therapeutics (NASDAQ: OREX) from Outperform to Sector Perform with a price target of $1.00 (from $5.00). Analyst Simos Simeonidis sees a tougher road for Contrave/ Mysimba.
"Despite the already significant decline in OREX shares, we are downgrading to Sector Perform on what we view as a bleak outlook for both the US... More
Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c
February 26, 2016 7:03 AM ESTOrexigen Therapeutics (NASDAQ: OREX) reported Q4 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $4.9 million versus the consensus estimate of $14.07 million.
According to IMS Health, 185,944 prescriptions of Contrave (naltrexone HCl and bupropion HCl extended-release... More
